2024
Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease
Sahyoun L, Fetene J, McMillan C, Protiva P, Al Bawardy B, Gaidos J, Proctor D. Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease. Digestive Diseases And Sciences 2024, 69: 1654-1660. PMID: 38466459, DOI: 10.1007/s10620-024-08355-3.Peer-Reviewed Original ResearchSevere COVID-19 infectionInflammatory bowel diseaseCOVID-19 infectionIBD flareIBD therapyCOVID-19 treatmentSingle-center retrospective study of adult patientsMethodsA single-center retrospective studyAdvanced therapiesRetrospective study of adult patientsBowel diseaseStudy of adult patientsInflammatory bowel disease therapyDevelopment of severe COVID-19 infectionSevere COVID-19Acute COVID-19Corticosteroid useNo significant differenceNo therapyAdult patientsSupplemental oxygenPrimary outcomeSecondary outcomesTherapyCorticosteroids
2023
Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease
Sayed A, Assis D, Silveira M, Deng Y, Ciarleglio M, Gaidos J, Proctor D, Al-Bawardy B. Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease. European Journal Of Gastroenterology & Hepatology 2023, 35: 270-274. PMID: 36708297, DOI: 10.1097/meg.0000000000002510.Peer-Reviewed Original ResearchConceptsPrimary sclerosing cholangitisInflammatory bowel diseasePSC-IBDEndoscopic healingTherapy groupAdvanced therapiesClinical remissionBowel diseaseAcute ascending cholangitisRate of cholangitisSmall bowel involvementThird of patientsAscending cholangitisSclerosing cholangitisAdult patientsBowel involvementSecondary outcomesMedian agePrimary outcomeRetrospective studyHigh riskCholangitisPatientsTherapyLarger study
2019
Mo1862 – No Increaed Rates of Adverse Ibd-Related Outcomes for Patients with IBD and Concomitant Prostate Cancer Treated with Radiation Therapy
Feagins L, Kim J, Chandrakumaran A, Gandle C, Naik K, Hou J, Yao M, Gaidos J. Mo1862 – No Increaed Rates of Adverse Ibd-Related Outcomes for Patients with IBD and Concomitant Prostate Cancer Treated with Radiation Therapy. Gastroenterology 2019, 156: s-867. DOI: 10.1016/s0016-5085(19)39129-2.Peer-Reviewed Original ResearchP071 NO INCREASED RATE OF ADVERSE IBD-RELATED OUTCOMES FOR PATIENTS WITH IBD AND CONCURRENT PROSTATE CANCER TREATED WITH RADIATION THERAPY
Feagins L, Kim J, Chandrakumaran A, Gandle C, Naik K, Hou J, Yao M, Gaidos J. P071 NO INCREASED RATE OF ADVERSE IBD-RELATED OUTCOMES FOR PATIENTS WITH IBD AND CONCURRENT PROSTATE CANCER TREATED WITH RADIATION THERAPY. Inflammatory Bowel Diseases 2019, 25: s34-s34. DOI: 10.1093/ibd/izy393.078.Peer-Reviewed Original ResearchP071 NO INCREASED RATE OF ADVERSE IBD-RELATED OUTCOMES FOR PATIENTS WITH IBD AND CONCURRENT PROSTATE CANCER TREATED WITH RADIATION THERAPY
Feagins L, Kim J, Chandrakumaran A, Gandle C, Naik K, Hou J, Yao M, Gaidos J. P071 NO INCREASED RATE OF ADVERSE IBD-RELATED OUTCOMES FOR PATIENTS WITH IBD AND CONCURRENT PROSTATE CANCER TREATED WITH RADIATION THERAPY. Gastroenterology 2019, 156: s49-s50. DOI: 10.1053/j.gastro.2019.01.130.Peer-Reviewed Original Research
2017
Incidence of and Predictors for Early Discontinuation of Biological Therapies in Veteran Patients with Inflammatory Bowel Disease
Feagins LA, Waljee A, Hou JK, Gu P, Kanjo S, Rudrapatna V, Cipher DJ, Govani S, Gaidos J. Incidence of and Predictors for Early Discontinuation of Biological Therapies in Veteran Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2017, 23: 1434-1439. PMID: 28570429, DOI: 10.1097/mib.0000000000001145.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseBiological therapyAdverse drug reactionsConcomitant thiopurinesPrimary nonresponseEarly discontinuationBowel diseaseDrug reactionsDiagnosis of IBDBiological agentsFirst biological agentRetrospective cohort studyInitiation of therapyCourse of therapyVA hospital systemIleocolonic diseaseVA cohortCohort studyVeteran patientsMedical recordsRisk factorsCommon reasonPatientsDiscontinuationTherapy
2016
Sa1885 Incidence of and Predictors for Early Discontinuation of Biologic Therapies in Veteran Patients with Inflammatory Bowel Disease
Feagins L, Waljee A, Hou J, Gu P, Kanjo S, Rudrapatna V, Ellis A, Govani S, Gaidos J. Sa1885 Incidence of and Predictors for Early Discontinuation of Biologic Therapies in Veteran Patients with Inflammatory Bowel Disease. Gastroenterology 2016, 150: s392. DOI: 10.1016/s0016-5085(16)31374-9.Peer-Reviewed Original Research